The combination of ET with a CDK4/6 inhibitor is the standard of care first line treatment for advanced ER+/HER2-breast cancer, and while practice changing and improving survival outcomes, patients eventually develop progressive disease due to intrinsic or acquired drug resistance. The gene discussed is ESR1; the disease is breast cancer.